UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers January 25, 2024
Accurus Biosciences and ImmPACT Bio Enter into an Exclusive Global License Agreement for a Potentially Best-in-Class CLDN18.2 Antibody January 25, 2024
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec -vncg) in the U.S. January 25, 2024
First Patient Treated in Ph 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 25, 2024
First Patient Enrolled in FIERCE-HN Trial of Ficlatuzumab + ERBITUX® (cetuximab) in Patients with HPV-negative R/M HNSCC January 25, 2024
